Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Maeda

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
BMJ Open|June 24, 2018
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) studyYasuo Okumura, Ikuo Fukuda, Mashio Nakamura, et al.
Circulation Reports|April 7, 2023
Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism - Subanalysis of the J'xactly StudyMashio Nakamura, Ikuo Fukuda, Norikazu Yamada, et al.
Annals of Vascular Diseases|October 2, 2023
Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J'xactly StudyNorikazu Yamada, Ikuo Fukuda, Mashio Nakamura, et al.
Scientific Reports|November 27, 2014
Nanoclusters synthesized by synchrotron radiolysis in concert with wet chemistryHiroyuki Oyanagi, Yuuichi Orimoto, Kuniko Hayakawa, et al.
Circulation Reports|August 29, 2022
Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism - Insights From the J'xactly StudyTakeshi Yamashita, Ikuo Fukuda, Mashio Nakamura, et al.
Phlebology|November 26, 2022
Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in JapanMakoto Mo, Ikuo Fukuda, Mashio Nakamura, et al.
Journal of Cardiology|November 18, 2022
Effectiveness and safety of rivaroxaban in patients with venous thromboembolism and active cancer: A subanalysis of the J'xactly studyShinji Hisatake, Takanori Ikeda, Ikuo Fukuda, et al.
Protein and Peptide Letters|April 8, 2003
Synthesis of chemotactic peptide analogs with a photoaffinity cross-linker as new probes for analysis of receptor-ligand interactionMitsukuni Shibue, Masahiro Yoshiki, Masaya Miyazaki, et al.
Circulation Reports|October 28, 2022
Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism - Subanalysis of the J'xactly StudyShinji Hisatake, Takanori Ikeda, Ikuo Fukuda, et al.
Thrombosis Journal|August 20, 2023
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly studyShohei Migita, Yasuo Okumura, Ikuo Fukuda, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
BMJ Open|June 24, 2018
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) studyYasuo Okumura, Ikuo Fukuda, Mashio Nakamura, et al.
Circulation Reports|April 7, 2023
Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism - Subanalysis of the J'xactly StudyMashio Nakamura, Ikuo Fukuda, Norikazu Yamada, et al.
Annals of Vascular Diseases|October 2, 2023
Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J'xactly StudyNorikazu Yamada, Ikuo Fukuda, Mashio Nakamura, et al.
Scientific Reports|November 27, 2014
Nanoclusters synthesized by synchrotron radiolysis in concert with wet chemistryHiroyuki Oyanagi, Yuuichi Orimoto, Kuniko Hayakawa, et al.
Circulation Reports|August 29, 2022
Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism - Insights From the J'xactly StudyTakeshi Yamashita, Ikuo Fukuda, Mashio Nakamura, et al.
Phlebology|November 26, 2022
Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in JapanMakoto Mo, Ikuo Fukuda, Mashio Nakamura, et al.
Journal of Cardiology|November 18, 2022
Effectiveness and safety of rivaroxaban in patients with venous thromboembolism and active cancer: A subanalysis of the J'xactly studyShinji Hisatake, Takanori Ikeda, Ikuo Fukuda, et al.
Protein and Peptide Letters|April 8, 2003
Synthesis of chemotactic peptide analogs with a photoaffinity cross-linker as new probes for analysis of receptor-ligand interactionMitsukuni Shibue, Masahiro Yoshiki, Masaya Miyazaki, et al.
Circulation Reports|October 28, 2022
Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism - Subanalysis of the J'xactly StudyShinji Hisatake, Takanori Ikeda, Ikuo Fukuda, et al.
Thrombosis Journal|August 20, 2023
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly studyShohei Migita, Yasuo Okumura, Ikuo Fukuda, et al.
Pageof 9